Promising Early Data and Strategic Expansion Bolster Buy Rating for uniQure’s AMT-260 Program

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on uniQure (QURE – Research Report) today and set a price target of $70.00.

Patrick Trucchio has given his Buy rating due to a combination of factors, primarily the promising early data from uniQure’s AMT-260 program. The initial results from a Phase 1/2a trial for mesial temporal lobe epilepsy (mTLE) showed a significant reduction in seizure frequency for the first patient treated, with a 92% decrease in seizures and no serious adverse events reported. This encouraging outcome suggests the potential for AMT-260 to address the unmet needs of patients with drug-refractory mTLE.
Additionally, the rational design of AMT-260, which uses a one-time, MRI-guided gene therapy to target seizure generation mechanisms, supports its continued development. The trial’s expansion to include more patients and the FDA’s approval to broaden eligibility criteria further bolster the program’s prospects. Trucchio’s valuation approach, using discounted cash flow and sum-of-the-parts methodologies, alongside a favorable risk assessment, underpins the $70 price target for uniQure’s stock.